FDA: Taking Receptor Blockers for High Blood Pressure Does Not Increase Risk of Cancer

FDA has determined that any concern about a relationship between ARB use and development of cancer has been resolved by this analysis.

The U.S. Food and Drug Administration announced that a group of medications used to control high blood pressure, called angiotensin receptor blockers (ARBs), do not increase the risk of developing cancer in patients using the medications.

In July 2010, FDA reported that a safety review of ARBs would be performed after a published study found a small increased risk of cancer in patients taking an ARB compared to those patients not taking an ARB.

For this safety review, FDA evaluated 31 randomized clinical trials, comparing patients taking an ARB to patients not taking an ARB, looking for the incidence of cancer.

“The FDA has completed its review of controlled trial data on more than 155,000 patients randomized to ARBs or other treatments—the largest evaluation of such data to date—and finds no evidence of an increased risk of cancer in patients who take an ARB,” said Mary Ross Southworth, deputy director for safety in the Division of Cardiovascular and Renal Drugs in the FDA’s Center for Drug Evaluation and Research.

ARBs are medications used alone or in combination with other medications to treat high blood pressure and other heart-related conditions. A complete list is available in a Drug Safety Communication.

Brand names include:

  • Atacand (candesartan)
  • Avapro (irbesartan)
  • Benicar (olmesartan)
  • Cozaar (losartan)
  • Diovan (valsartan)
  • Micardis (telmisartan)
  • Teveten (eprosartan)
  • Several combination drug products

Sustained elevated blood pressure (hypertension) increases the risk of death, heart attacks, stroke, heart failure, and kidney failure. That is why it is important to keep blood pressure at normal levels. There are many treatments available to control elevated blood pressure and ARBs are an important group of such treatments.

FDA has determined that any concern about a relationship between ARB use and development of cancer has been resolved by this analysis. People currently taking any antihypertensive medication should not stop taking it without talking to their health care professional first.

For more information, go to Drug Safety Communication: Safety review update of angiotensin receptor blockers (ARBs) and cancer and Angiotensin Receptor Blockers (ARBs) Information.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Easy to Use Safety Incident App

    Record incidents on the go with IndustrySafe’s mobile app. Collect data for multiple types of incidents including including near misses, vehicle and environmental incidents, and employee and non-employee injuries; at job sites and remote locations—with or without web access.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. IndustrySafe is here to help. We put together a resource that’s easy to digest so you can get answers to your training questions and ensure you're complying with OSHA's standards.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Industry Safe
comments powered by Disqus